Lupin Limited · NSE:LUPIN
Lupin — Q1 FY2025 Earnings Presentation
21 slides from Lupin's earnings presentation, Aug 6, 2024
Slide 1: Stock exchange cover letter – Investor Presentation Q1 FY25
August 6, 2024 BSE Limited P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Dear Sir/Madam, Sub: Investor Presentation – Q1 FY25. Pursuant to Regulation 30(2) read wi
Slide 2: Investor Presentation Q1 FY25
Investor Presentation Q1 FY25 Aug 6, 2024
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Q1FY25 Performance
hd LUPIN QIFY25 Perfor
Slide 5: Q1FY25: Key Growth Metrics
Q1FY25: Key Growth Metrics Strong execution on all fronts Key Metrics Business Performance INR mn India North America 55,143 mn 19,259 mn 20,408 mn Sales 18% YoY 28% YoY 16% / 22% YoY2 12,864 mn 23.3% Growth Markets EMEA EBITDA1 Margin 5,151 mn 5,031 mn 27% YoY 26% YoY 50% / 98% YoY2 API ROW 8,013 m
Slide 6: Q1FY25: Key Developments
Q1FY25: Key Developments Consistent trajectory of improved profitability Financials Key Launches Sales* and EBITDA margin Trajectory Lupin’s first Mirabegron Generic of Rymti® biosimilar in 60,000 55,143 30.0% (25mg) Myrbetriq® (Etanercept) Canada 49,392 50,799 48,951 50,000 45,369 25.0% Business De
Slide 7: Q1FY25 Financial Snapshot
Q1FY25 Financial Snapshot Sales Mix Key Financials INR mn Revenue (In INR mn and %) India, Q1 FY25 Q1 FY24 Q4 FY24 19,259, North 35% America, 20,408, 37% Sales 55,143 47,4212 48,951 API, 3,622, 7% EBITDA1 12,864 8,5652 9,968 Growth ROW, EMEA, Markets, 1,672, 5,031, 5,151, 9% Net Income 8,013 4,5232
Slide 8: India: Outperforming market growth
India: Outperforming market growth Leveraging chronic leadership with improved India business grew ~18% YoY in Q1FY25 productivity India Sales (INR mn) 16,384 16,915 17,251 16,015 19,259 #2 rank #3 rank #3 rank Respiratory Diabetes Care Cardiac • Chronic share ~62% of sales • Total sales force 9,876
Slide 9: India: Amplifying our Core
India: Amplifying our Core Lupin prescription business is positioned to outperform Enabling end to end healthcare ecosystem and access IPM with key drivers in place for the patient Enhancing penetration and reach CHC Portfolio catering to GI, • Maximizing Chronic therapy focus Business Verticals VMS
Slide 10: North America: Delivering on Complex Generics
North America: Delivering on Complex Generics Leadership: 4.4% TRx Consistent ramp up in sales Growing Respiratory volume share in U.S.1 portfolio US Sales ($mn) 181 213 212 209 227 #3 #1 22.3% 26.1% in the US1 in 50 products2 Albuterol Arfomoterol Q1 Q2 Q3 Q4 Q1 market share market share Maintainin
Slide 11: Other Markets: Key Highlights
Other Markets: Key Highlights Consistent performance in developed markets Emerging Markets • Strong double-digit growth witnessed in UK & Germany • BRL 61mn sales4 in Q1FY25 EU Brazil • Rank 2nd in reference market3 • Growth driven by higher Luforbec® & NaMuscla® • 8th largest generics player1 • Rev
Slide 12: Innovation and Quality
Innovation and Quality R&D pivoting towards complex generics and Achieve Best-in-Class Quality biosimilars Substantial Capabilities to become CGx powerhouse Recent Track Record • Inhalation: Global presence with end-to-end capabilities Successful outcomes in last 12 months of MDIs, DPIs, Soft-Mist I
Slide 13: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend R&D (INR mn) Capex (INR mn) Net debt/ Equity 4,500 4,255 15.0% 2,000 1,848 15.0% 0.16 0.14 4,000 3,679 3,764 3,567 3,500 13.0% 1,800 13.0% 0.14 3,500 1,600 11.0% 1,345 11.0% 0.12 3,000 1,400 1,171 0.10 2,500 9.0% 1,200 1,059 1,117 9.0% 0.10 8.7% 7.0% 1,000 7.0%
Slide 14: P&L Highlights Q1 FY25
P&L Highlights Q1 FY25 YoY QoQ Amount in INR mn Q1’FY25 % of Sales Q1’FY24 % of Sales Q4’FY24 % of Sales Growth Growth Net Sales 55,143 100.00% 47,421 100.00% 16.3% 48,951 100.00% 12.6% Other operating income 860 1.6% 720 1.52% 19.4% 657 2.31% 30.9% Total revenue 56,003 101.6% 48,141 101.52% 16.33%
Slide 15: Lupin at a Glance
hd LUPIN Lupin at a ¢
Slide 16: Lupin Today
Lupin Today Operating from a position of strength Global Presence Local Leadership Geographically Diverse (FY24 Sales) 10th Largest in 7th India Pharma 9% Largest Generic 3 rd the US Market Rank 34% INDIA Developed Company (by prescriptions2) Markets (by sales4) (by sales1) 37% Largest Largest US $2
Slide 17: Vision
Vision A pharmaceutical company focused on delivering high quality medicines to patients around the world Global Other United Developed India Region Emerging API States Markets Markets Evolving portfolio and Global operational Delivering innovative pipeline in Complex Global reach and scale as effic
Slide 18: Lupin's ESG Update
Lupin’s ESG Update Our Commitment to Responsible Business Practices, Sustainability, Environmental Stewardship and Risk Management Our Sustainability initiatives have extended their impact across our entire value chain resulting in significant positive impacts 100% sites in India successfully covere
Slide 19: ESG: Ratings update in FY24
ESG: Ratings update in FY24 Committed to accountability and public disclosure of ESG initiatives and metrics Lupin has made progress in ratings in 2023 responses in both S&P Global CSA and featured as a Yearbook Member 2024 and scored B in CDP Climate and C in Water Agency 2021 2022 2023 Trends ESG
Slide 20: Lupin – Awards and Accolades
Lupin – Awards and Accolades • ‘Breakthrough Launch of the Year’ Award (brand Valentas) at the National Feather Healthcare and Pharma Awards in association with the Economic Times • Humrahi, Lupin’s Patient Support Program for Diabetes Management, recognized as a ‘Patient-Centric Pharma Program in D
Slide 21: Thank You
Thank You Registered Address 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai - 400055, India Phone: +91 22664 02323 | Fax: +91 22664 02051 lupin.com youtube.com/c/LupinGlobal x.com/LupinGlobal facebook.com/LupinWorld/ linkedIn.com/company/lupin